IBANDRONIC ACID MYLAN

150 Milligram Film Coated Tablet

McDermott Laboratories Ltd t/a Gerard LaboratoriesPA0577/111/001

SPC: DATE OF REVISION OF THE TEXT

18 May 2015 - 22 May 2016	22 May 2016 - Present
January 2014	May 2016

« Back

Follow medicine

Print

Latest Changes to Medicine Info & SPC

28 Jul 2016
Marketing Status
22 May 2016
SPC: DATE OF REVISION OF THE TEXT
22 May 2016
SPC: MARKETING AUTHORISATION NUMBER
22 May 2016
SPC: Special precautions for disposal and other handling
22 May 2016
SPC: Preclinical safety data
22 May 2016
SPC: Pharmacokinetic properties
22 May 2016
SPC: Pharmacodynamic properties
22 May 2016
SPC: Overdose
22 May 2016
SPC: Undesirable effects
22 May 2016
SPC: Effects on ability to drive and use machines
22 May 2016
SPC: Fertility, pregnancy and lactation
22 May 2016
SPC: Interaction with other medicinal products and other forms of interaction
22 May 2016
SPC: Special warnings and precautions for use
22 May 2016
SPC: Contraindications
22 May 2016
SPC: Posology and method of administration
22 May 2016
SPC: PHARMACEUTICAL FORM
22 May 2016
SPC: QUALITATIVE AND QUANTITATIVE COMPOSITION
22 May 2016
SPC: NAME OF THE MEDICINAL PRODUCT
20 May 2016
Marketing Status

Please note changes to the medicine information and summary of product characteristics are only available from the 19/05/2015 onwards. Changes made before this date aren't available online.

IBANDRONIC ACID MYLAN

SPC: DATE OF REVISION OF THE TEXT

Latest Changes to Medicine Info & SPC

Important information regarding cookies and the HPRA